View clinical trials related to Edema.
Filter by:The AquaPass is a non-invasive, renal-intended system designed to enhance fluid transfer through the skin, by increasing sweat rate, to treat fluid overload in heart failure patients. This study will further evaluate the safety, efficacy, and usability of the AquaPass system in the hospital and home settings.
The purpose of this research study is to observe the patient's clinical care and how EYLEA® HD is used as a treatment in real-world settings. Patients are asked to join the study because they have either neovascular age-related macular degeneration (nAMD/wet age-related macular degeneration [AMD]) or diabetic macular edema (DME). Patients cannot have used EYLEA® HD in the past and the doctor must be planning to treat nAMD or DME with a new prescription of EYLEA® HD (aflibercept 8 mg).
1. assessment the outcomes of vitrectomy on retinal function by mf-ERG (multifocal electroretinogram) and anatomy by OCT (optical coherence tomography) in patients with tractional diabetic macular edema (TDME) . 2. To correlate the postoperative corrected distance visual acuity (CDVA) with the mf-ERG and OCT findings following vitrectomy surgery for TDME.
A multi-center, early feasibility study of using the Mechanical Tissue Resuscitation™ (MTR™) therapy system for removal of excess fluid in subjects who have had a portion of their skull removed to expose the dura/brain and require drainage for fluid removal.
A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept
Lymphedema is an inflammatory disease characterized by abnormal accumulation of excess water, plasma proteins, as well as extravascular blood and parenchymal cells in the affected upper and lower arms, chest and/or trunk due to inadequate lymphatic carrying capacity, associated with high-severity, recurrent soft tissue infections that can lead to sepsis and even death. It is a disease. Although there is no definitive treatment for lymphedema disease, a Complex Decongestive Treatment approach, including manual lymph drainage, skin care, special exercises, compression and self-care, has been defined to slow the progression of the disease and prevent secondary complications. In addition, similar to vagus nerve activation with manual lymphatic drainage, parasympathetic nerve activation has been defined. system activation can be increased. The aim of our study is to examine the effect of transcutaneous auricular vagus nerve stimulation on quality of life, grip strength and dexterity in unilateral upper extremity lymphedema patients. It was planned as a randomized controlled experimental study. The population of the study will be lymphedema patients in Gaziosmanpaşa Physical Therapy Rehabilitation Training and Research Hospital, and the sample will be 27 volunteer patients who meet the inclusion and exclusion criteria. The study was planned as a single center (Gaziosmanpaşa Training and Research Hospital). Participants will be randomly divided into three groups. Subjects will be instructed to draw an envelope from a secret box. Each envelope will contain a yellow, red and blue card and they will be assigned to one of the 3 groups of the study accordingly. Only the Complex Decongestive Treatment (manual lymph drainage, skin care, special exercises, compression) approach will be applied to the first group, Complex Decongestive Treatment and sham transcutaneous vagus nerve stimulation to the second group, and transcutaneous vagus nerve stimulation in addition to Complex Decongestive Treatment to the third group. The third party who has access to the box containing the envelopes will not be involved in the study. The data collected from the patients will be entered into the SPSS 21.0 package program, a data set will be created and statistical analyzes will be performed.
Purpose of the study：This study aimed to evaluate the clinical significance of serum SUR1, TRPM4 and MMP-9 in the diagnosis of cerebral edema in children with cerebral edema admitted to PICU by comparing them with CT results and perturbation coefficients, so as to provide biological indicators for clinical diagnosis of cerebral edema and provide targets for the treatment of cerebral edema in various diseases.
The purpose of this study is to generate additional safety and effectiveness data in Indian Diabetic macular edema (DME) patients that more closely resemble the real-world population intended to be treated with Brolucizumab. This study is being conducted as part of the post-marketing regulatory commitment to the Indian Health authority.
This multicenter, non-randomized, open-label, multiple-dose-escalation and dose-expansion study will investigate the safety, tolerability, pharmacokinetics and efficacy of ASKG712 following intravitreal administration in patients with diabetic macular edema (DME).
A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema